Up-regulation of the PI3K/AKT and RHO/RAC/PAK signalling pathways in CHK1 inhibitor resistant Eµ-Myc lymphoma cells
Open Access
- 14 October 2022
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 479 (19) , 2131-2151
Abstract
The development of resistance and the activation of bypass pathway signalling represents a major problem for the clinical application of protein kinase inhibitors. While investigating the effect of either a c-Rel deletion or RelAT505A phosphosite knockin on the Eµ-Myc mouse model of B-cell lymphoma, we discovered that both NF-κB subunit mutations resulted in CHK1 inhibitor resistance, arising from either loss or alteration of CHK1 activity, respectively. However, since Eµ-Myc lymphomas depend on CHK1 activity to cope with high levels of DNA replication stress and consequent genomic instability, it was not clear how these mutant NF-κB subunit lymphomas were able to survive. To understand these survival mechanisms and to identify potential compensatory bypass signalling pathways in these lymphomas, we applied a multi-omics strategy. With c-Rel−/− Eµ-Myc lymphomas we observed high levels of Phosphatidyl-inositol 3-kinase (PI3K) and AKT pathway activation. Moreover, treatment with the PI3K inhibitor Pictilisib (GDC-0941) selectively inhibited the growth of reimplanted c-Rel−/− and RelAT505A, but not wild type (WT) Eµ-Myc lymphomas. We also observed up-regulation of a RHO/RAC pathway gene expression signature in both Eµ-Myc NF-κB subunit mutation models. Further investigation demonstrated activation of the RHO/RAC effector p21-activated kinase (PAK) 2. Here, the PAK inhibitor, PF-3758309 successfully overcame resistance of RelAT505A but not WT lymphomas. These findings demonstrate that up-regulation of multiple bypass pathways occurs in CHK1 inhibitor resistant Eµ-Myc lymphomas. Consequently, drugs targeting these pathways could potentially be used as either second line or combinatorial therapies to aid the successful clinical application of CHK1 inhibitors.Keywords
This publication has 83 references indexed in Scilit:
- The Proteomics Identifications (PRIDE) database and associated tools: status in 2013Nucleic Acids Research, 2012
- Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathwayGenes & Development, 2012
- MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomicsNature Methods, 2011
- The role of RelA (p65) threonine 505 phosphorylation in the regulation of cell growth, survival, and migrationMolecular Biology of the Cell, 2011
- USP1 deubiquitinase maintains phosphorylated CHK1 by limiting its DDB1-dependent degradationHuman Molecular Genetics, 2011
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaProceedings of the National Academy of Sciences, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- IKK and NF‐κB‐mediated regulation of Claspin impacts on ATR checkpoint functionThe EMBO Journal, 2010
- DNA replication stress, genome instability and agingNucleic Acids Research, 2007